Strong portfolio of novel antibody-based cancer therapies
Oxford BioTherapeutics is focused on developing innovative antibody-based cancer treatments, based on a range of proprietary technologies. These target a number of oncology indications, with a particular focus on cancers with limited treatment options. These include a mixture of solid and liquid malignancies, such as acute myeloid leukemia and breast, ovarian and lung cancers. We aim to accelerate the development of our pipeline by designing studies with rapid clinical readouts and moving to pivotal trials as soon as possible following successful proof-of-concept results.